Indications
Lazcluze in combination with amivantamab is indicated for the first line treatment of adult patients with advanced non small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations.
Composition
- Active substance
- lazertinib mesilate monohydrate
- International name (INN)
- lazertinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lazcluze
- Active substance
- lazertinib mesilate monohydrate
- ATC code
- L01EB09
- Therapeutic area
- Carcinoma, Non-Small-Cell Lung